52 patients thought to have sarcoid heart involvement have been followed up. By administration of a standardized glucocorticoid therapy we demonstrated improvement of patients' symptoms, ECG disturbances, thallium scan defects of left heart muscle and there was 60-70% regression of pulmonary sarcoidosis. There was a low death rate. We conclude that our diagnostic measures are reliable, and that glucocorticoid therapy is efficacious in the early stages of the disease.

The results of stimulation threshold analysis carried out in 230 patients after the initial electrode implantation, and in 188 patients during pacemaker replacement, are presented. The electrodes investigated were the IE-60K-10 (279 cases), the IE-60-K (96 cases) and the ME-50 (26 cases). The chronic stimulation threshold voltage for the electrode IE-60K-10 (electrode surface area: 10 mm2) at a pulse width of 0.5 ms, after an electrode function time of 25 months, is 2.05 +/- 0.18 V, representing 256% of the acute threshold, and is equally as high as the chronic figure for the IE-60-K electrode (surface area: 27 mm2) measured at 2.08 +/- 0.20 V. The current threshold for the IE-60K-10 increased from 0.78 +/- 0.07 mA by 299% to 2.33 +/- 0.30 mA and was thus, as expected, lower than that of the large area electrode IE-60-K, which increased from 1.11 +/- 0.22 mA to 3.23 +/- 0.43 mA (291%). On the basis of the computation of the stimulation threshold energy and the stimulation threshold charge, a reduction of pulse duration to below 0.5 ms would not appear to make such energy-saving sense.

No abstract